{"id":"https://openalex.org/W2887936809","doi":"https://doi.org/10.1158/1538-7445.am2018-1684","title":"Abstract 1684: Selective SIRPa blockade potentiates dendritic cell antigen cross-presentation and triggers memory T-cell antitumor responses","display_name":"Abstract 1684: Selective SIRPa blockade potentiates dendritic cell antigen cross-presentation and triggers memory T-cell antitumor responses","publication_year":2018,"publication_date":"2018-07-01","ids":{"openalex":"https://openalex.org/W2887936809","doi":"https://doi.org/10.1158/1538-7445.am2018-1684","mag":"2887936809"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2018-1684","doi":"https://doi.org/10.1158/1538-7445.am2018-1684","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-1684","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012547336","display_name":"Vanessa Gauttier","orcid":"https://orcid.org/0000-0002-4297-0449","observed_orcids":["https://orcid.org/0000-0002-4297-0449"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vanessa Gauttier","raw_affiliation_strings":["1OSE Immunotherapeutics, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1OSE Immunotherapeutics, Nantes, France;","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011981371","display_name":"Sabrina Pengam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sabrina Pengam","raw_affiliation_strings":["1OSE Immunotherapeutics, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1OSE Immunotherapeutics, Nantes, France;","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029438699","display_name":"Justine Durand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Justine Durand","raw_affiliation_strings":["2INSERM UMR1064, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2INSERM UMR1064, Nantes, France","institution_ids":["https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023411196","display_name":"Aurore Morello","orcid":"https://orcid.org/0000-0003-3202-3779","observed_orcids":["https://orcid.org/0000-0003-3202-3779"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Aurore Morello","raw_affiliation_strings":["1OSE Immunotherapeutics, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1OSE Immunotherapeutics, Nantes, France;","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018875160","display_name":"Sophie Conchon","orcid":"https://orcid.org/0000-0003-2602-3385","observed_orcids":["https://orcid.org/0000-0003-2602-3385"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Sophie Conchon","raw_affiliation_strings":["2INSERM UMR1064, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2INSERM UMR1064, Nantes, France","institution_ids":["https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080154745","display_name":"Bernard Vanhove","orcid":"https://orcid.org/0000-0002-2872-8648","observed_orcids":["https://orcid.org/0000-0002-2872-8648","https://orcid.org/0000-0001-7955-6842"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Bernard Vanhove","raw_affiliation_strings":["1OSE Immunotherapeutics, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1OSE Immunotherapeutics, Nantes, France;","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048543389","display_name":"Nicolas Poirier","orcid":"https://orcid.org/0000-0003-2335-9385","observed_orcids":["https://orcid.org/0000-0003-2335-9385"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nicolas Poirier","raw_affiliation_strings":["1OSE Immunotherapeutics, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1OSE Immunotherapeutics, Nantes, France;","institution_ids":["https://openalex.org/I4210101439"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"78","issue":"13_Supplement","first_page":"1684","last_page":"1684"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12672","display_name":"Phagocytosis and Immune Regulation","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.09309999644756317,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.03240000084042549,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd47","display_name":"CD47","score":0.9459999799728394},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7149999737739563},{"id":"https://openalex.org/keywords/memory-t-cells","display_name":"memory T cells","score":0.8299999833106995},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.8169999718666077},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.859000027179718},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.7360000014305115},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.6010000109672546},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.5630000233650208},{"id":"https://openalex.org/keywords/myeloid-cells","display_name":"myeloid cells","score":0.6650000214576721},{"id":"https://openalex.org/keywords/innate-immunity","display_name":"innate immunity","score":0.34299999475479126},{"id":"https://openalex.org/keywords/adoptive-immunotherapy","display_name":"adoptive immunotherapy","score":0.44999998807907104}],"concepts":[{"id":"https://openalex.org/C193419808","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired immune system","level":3,"score":0.658579409122467},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6512855291366577},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.606151282787323},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5514671206474304},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5461819767951965},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5459585785865784},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.5344265103340149},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5158151984214783},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5141937732696533},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49237191677093506},{"id":"https://openalex.org/C2780104668","wikidata":"https://www.wikidata.org/wiki/Q21108354","display_name":"CD47","level":3,"score":0.47130000591278076},{"id":"https://openalex.org/C2778170410","wikidata":"https://www.wikidata.org/wiki/Q506253","display_name":"Dendritic cell","level":3,"score":0.4554542899131775},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.448127418756485},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.44204580783843994},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.44026079773902893},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4108763337135315},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.24183949828147888},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1291249394416809}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2018-1684","doi":"https://doi.org/10.1158/1538-7445.am2018-1684","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2018-1684","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2739520144","https://openalex.org/W4231749109","https://openalex.org/W4404065556","https://openalex.org/W3002193235","https://openalex.org/W3211573504","https://openalex.org/W4399381314","https://openalex.org/W4285097218","https://openalex.org/W4416449677","https://openalex.org/W3190800547","https://openalex.org/W2594014934"],"abstract_inverted_index":{"Abstract":[0],"Targeting":[1,76],"immune":[2,28,59,81,102,123,189,295],"checkpoints":[3],"of":[4,21,44,61,69,95,164,215,274,309,408],"the":[5,52,62,67,93,157,264,409],"adaptive":[6,78,101,122,213,373],"immunity":[7],"has":[8],"shown":[9,146],"great":[10],"therapeutic":[11,86],"efficacy":[12],"to":[13,162,198,271],"fight":[14],"cancers,":[15],"but":[16],"in":[17,31,66,105,117,119,133,140,166,172,206,228,258,304,370],"a":[18,26,40,84,96,147,192],"limited":[19],"proportion":[20],"patients.":[22],"Myeloid":[23],"cells":[24,82,262,288,292,317,328],"represent":[25],"major":[27],"cell":[29,361,396],"type":[30],"many":[32],"solid":[33],"tumors,":[34],"and":[35,71,79,107,178,290,321,334,346,364,399],"are":[36],"often":[37],"associated":[38],"with":[39,51,121,152,160,176,180,239,245,263,297,372],"poor":[41],"outcome.":[42],"Interaction":[43],"SIRPalpha":[45],"(SIRPa),":[46],"expressed":[47],"by":[48,253,314],"myeloid":[49],"cells,":[50],"ubiquitous":[53],"receptor":[54],"CD47":[55],"is":[56],"an":[57,134,272],"important":[58],"checkpoint":[60,98,124],"innate":[63,80],"response,":[64],"involved":[65],"regulation":[68],"macrophages":[70],"neutrophils":[72],"functions":[73],"including":[74],"phagocytosis.":[75],"both":[77,104,173],"represents":[83],"promising":[85],"strategy":[87],"against":[88],"cancer.":[89],"Here":[90],"we":[91,302,353],"evaluated":[92,116],"impact":[94],"SIRPa":[97,153,310,357,392],"inhibitor":[99],"on":[100],"responses":[103,404],"rodents":[106],"human":[108,326,335],"settings.":[109],"Antagonist":[110],"anti-SIRPa":[111],"monoclonal":[112],"antibody":[113],"(mAbs)":[114],"was":[115,204],"vivo":[118],"combination":[120,151,269,371],"inhibitors":[125],"(anti-PD-L1":[126],"mAb)":[127,132],"or":[128,221,325],"costimulatory":[129],"agent":[130],"(anti-4-1BB":[131],"orthotopic":[135,235],"hepatocellular":[136],"carcinoma":[137],"(HCC)":[138],"model":[139],"immunocompetent":[141],"mice.":[142],"Whereas":[143],"monotherapies":[144],"have":[145],"modest":[148],"clinical":[149],"effect,":[150],"blockade":[154,308,393],"dramatically":[155],"enhanced":[156],"overall":[158],"survival":[159],"up":[161,197],"70%":[163],"mice":[165,185,208,227,231],"complete":[167],"remission":[168],"(p":[169],"<":[170],"0.0001":[171],"combination:":[174],"n=15":[175],"anti-41BB":[177],"n=11":[179],"anti-PDL1":[181],"combination).":[182],"These":[183],"cured":[184,226],"showed":[186,256,354],"robust":[187,366],"memory":[188,275,368,401],"response":[190,369],"since":[191],"second":[193],"tumor":[194],"challenge":[195],"(performed":[196],"one":[199],"month":[200],"after":[201],"treatment":[202],"withdrawal)":[203],"rejected":[205],"all":[207],"(p<0.01":[209],"n=20).":[210],"In":[211,351],"addition,":[212],"transfer":[214],"T":[216,261,277,291],"lymphocytes":[217],"from":[218,223,234,241,247,339],"4-1BB":[219,242,265],"combo":[220,225],"sera":[222,246],"PD-L1":[224,248,268],"na\u00efve":[229],"untreated":[230],"protected":[232],"them":[233],"HCC":[236],"development":[237],"(n=5/6":[238],"T-cell":[240,337,344,402],"combo;":[243],"n=5/5":[244],"combo).":[249],"Tumor":[250,279],"infiltrates":[251],"analyzed":[252],"flow":[254],"cytometry":[255],"enrichment":[257],"effector":[259],"CD8":[260],"therapy":[266],"whereas":[267],"led":[270],"accumulation":[273],"CD4":[276],"cells.":[278],"transcriptional":[280],"analysis":[281],"using":[282],"Nanostring":[283],"technology":[284],"revealed":[285],"higher":[286],"dendritic":[287,316,327,360,395],"(DCs)":[289],"(mainly":[293],"TH1)":[294],"signature":[296],"reduced":[298],"exhaustion":[299],"signature.":[300],"Finally,":[301],"found":[303],"vitro":[305],"that":[306,355],"selective":[307,356],"during":[311],"antigen":[312,397],"processing":[313],"mouse":[315],"(with":[318,329],"ovalbumin":[319],"protein":[320],"TCR-transgenic":[322],"OT-1":[323],"T-cell)":[324],"melan-A":[330],"25-mer":[331],"long":[332],"peptide":[333],"antigen-specific":[336],"clone":[338],"melanoma":[340],"patients)":[341],"significantly":[342],"increases":[343],"activation":[345],"cytokine":[347],"(i.e.":[348],"IFNg)":[349],"secretion.":[350],"conclusion,":[352],"antagonist":[358],"increased":[359],"tumor-antigen":[362],"cross-presentation":[363,398],"generated":[365],"antitumor":[367,403],"immunotherapies.":[374],"Citation":[375],"Format:":[376],"Vanessa":[377],"Gauttier,":[378],"Sabrina":[379],"Pengam,":[380],"Justine":[381],"Durand,":[382],"Aurore":[383],"Morello,":[384],"Sophie":[385],"Conchon,":[386],"Bernard":[387],"Vanhove,":[388],"Nicolas":[389],"Poirier.":[390],"Selective":[391],"potentiates":[394],"triggers":[400],"[abstract].":[405],"In:":[406],"Proceedings":[407],"American":[410],"Association":[411],"for":[412],"Cancer":[413,426],"Research":[414],"Annual":[415],"Meeting":[416],"2018;":[417],"2018":[418],"Apr":[419],"14-18;":[420],"Chicago,":[421],"IL.":[422],"Philadelphia":[423],"(PA):":[424],"AACR;":[425],"Res":[427],"2018;78(13":[428],"Suppl):Abstract":[429],"nr":[430],"1684.":[431]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2018-08-22T00:00:00"}